RU2530617C2 - Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy - Google Patents
Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy Download PDFInfo
- Publication number
- RU2530617C2 RU2530617C2 RU2012149873/15A RU2012149873A RU2530617C2 RU 2530617 C2 RU2530617 C2 RU 2530617C2 RU 2012149873/15 A RU2012149873/15 A RU 2012149873/15A RU 2012149873 A RU2012149873 A RU 2012149873A RU 2530617 C2 RU2530617 C2 RU 2530617C2
- Authority
- RU
- Russia
- Prior art keywords
- gestation
- herpes virus
- virus infection
- trimester
- human immunoglobulin
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229940076279 serotonin Drugs 0.000 title claims abstract description 16
- 230000035935 pregnancy Effects 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 6
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title claims description 14
- 210000005259 peripheral blood Anatomy 0.000 title claims description 5
- 239000011886 peripheral blood Substances 0.000 title claims description 5
- 238000009177 immunoglobulin therapy Methods 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 7
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims abstract description 4
- 230000036266 weeks of gestation Effects 0.000 claims description 6
- 230000005713 exacerbation Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 206010019972 Herpes viral infections Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Цель исследования - показать, что своевременное введение внутривенно беременным человеческого иммуноглобулина при обострении во II триместре герпес-вирусной инфекции снижает к концу беременности содержание в периферической крови серотонина.The aim of the study was to show that timely administration of a human immunoglobulin intravenously to pregnant women during exacerbation in the second trimester of herpes virus infection reduces the content of serotonin in peripheral blood by the end of pregnancy.
Как известно биогенноактивные вещества типа серотонина активно вырабатываются в ядрах центральной нервной системы: гипоталамус, черепно-мозговые узлы, нервные клетки спинальных ганглиев и ганглиев малого таза [3, 8, 9]. Определенный интерес вызывает явление повышенного содержания серотонина в гомогенате плаценты и в крови во время беременности, осложненной герпес-вирусной инфекцией [1].As you know, biogenic active substances such as serotonin are actively produced in the nuclei of the central nervous system: the hypothalamus, cranial nodes, nerve cells of the spinal ganglia and pelvic ganglia [3, 8, 9]. Of particular interest is the phenomenon of increased serotonin in the homogenate of the placenta and in the blood during pregnancy, complicated by herpes virus infection [1].
Следует отметить, что вирус герпеса как персистирующая инфекция в латентный и хронический период локализуется также в ядрах центральной и периферической нервной системы [3, 5, 6, 7]. Беременность с ее гормональной перестройкой в организме женщины является фактором, активизирующим герпес-вирусную инфекцию, что в свою очередь приводит к нарастанию выработки в ядрах центральной нервной системы серотонина [5]. Поэтому задачей нашего исследования и явилось применить средства к снижению активности герпес-вирусной инфекции и ее влияния на выработку серотонина.It should be noted that the herpes virus as a persistent infection in the latent and chronic periods is also localized in the nuclei of the central and peripheral nervous system [3, 5, 6, 7]. Pregnancy with its hormonal rearrangement in a woman’s body is a factor activating a herpes virus infection, which in turn leads to an increase in production of serotonin in the nuclei of the central nervous system [5]. Therefore, the objective of our study was to use means to reduce the activity of herpes virus infection and its effect on the production of serotonin.
Исследования проводились на протяжении II и III триместров гестации у 16 беременных, у которых отмечалась вспышка герпес-вирусной инфекции на 12 неделе гестации. После лечения проводилось повторное обследование беременных на 36 неделе беременности с целью выявления содержания в крови серотонина.Studies were conducted during the second and third trimesters of gestation in 16 pregnant women who had an outbreak of herpes virus infection at 12 weeks of gestation. After treatment, pregnant women were re-examined at 36 weeks of gestation in order to detect serotonin levels in the blood.
Заявленный способ имеет следующие приемы:The claimed method has the following techniques:
1. Исследования проводились на базе стационара акушерского отделения ФГБУ Дальневосточного научного центра физиологии и патологии дыхания СО РАМН. Обследовано 16 беременных, у которых отмечалось обострение герпес-вирусной инфекции во втором триместре на 12 неделе гестации с титром антител к вирусу герпеса 1:6400. Контролем служили 10 беременных, которые не болели на протяжении всего периода гестации. Все исследования были проведены с учетом требований Хельсинской декларации Всемирной ассоциации «Этические принципы проведения научных медицинских исследований с участием человека» с поправками 2000 г. и «Правилами клинической практики в Российской Федерации», утвержденными Приказом Минздрава РФ от 19.06.2003 г. №266.1. The studies were carried out on the basis of the hospital of the obstetric department of the Federal State Budgetary Institution of the Far Eastern Scientific Center for Physiology and Respiratory Pathology SB RAMS. We examined 16 pregnant women who exacerbated herpes virus infection in the second trimester at 12 weeks of gestation with a titer of antibodies to the herpes virus 1: 6400. The control was 10 pregnant women who were not ill during the entire gestation period. All studies were carried out taking into account the requirements of the Helsinki Declaration of the World Association “Ethical Principles for Conducting Scientific Medical Research with Human Participation” as amended in 2000 and the “Rules of Clinical Practice in the Russian Federation”, approved by Order of the Ministry of Health of the Russian Federation of June 19, 2003 No. 266.
2. Титр антител к вирусу герпеса анализировался с позиций активности герпес-вирусной инфекции в организме беременной по величине четырехкратного и более нарастания титра антител IgG к ВПГ-1, выявляемого в динамике через 10 дней в парных сыворотках. Титр антител определяли иммуноферментным методом на спектрофотометре «Stat-Fax» (USA).2. The titer of antibodies to the herpes virus was analyzed from the standpoint of the activity of herpes virus infection in the pregnant woman’s body by the magnitude of four or more increase in the titer of IgG antibodies to HSV-1, detected in dynamics after 10 days in paired sera. The antibody titer was determined by enzyme immunoassay on a Stat-Fax spectrophotometer (USA).
3. Содержание серотонина в крови определяли по методу Прошиной Л.Я. [4].3. The content of serotonin in the blood was determined by the method of Proshina L.Ya. [four].
4. Для лечения применяли стандартно выпускаемый человеческий иммуноглобулин, который вводили внутривенно капельно по 25 мл трижды через день на 16 неделе беременности и повторно на 24 неделе также по 25 мл внутривенно капельно трижды через день. Применяли иммуноглобулин человека, выпущенный Нижегородским предприятием «МинБио», филиал ФГУП НПО «Микроген» МЗ РФ.4. For treatment, a standardly released human immunoglobulin was used, which was administered intravenously 25 ml three times every other day at 16 weeks of gestation and again at 24 weeks also 25 ml intravenously three times every other day. We used human immunoglobulin produced by the Nizhny Novgorod enterprise "MinBio", a branch of the FSUE NPO "Microgen" of the Ministry of Health of the Russian Federation.
Исследования показали, что после обострения герпес-вирусной инфекции у беременной определяли в периферической крови титр антител к вирусу герпеса 1:6400, а содержание серотонина составляло 1,72±0,09 мкмоль/л, после лечения иммуноглобулином на 16 и 24 неделях титр антител к вирусу герпеса на 36 неделе гестации снизился до 1:1600, а количество серотонина в периферической крови составило 0,56±0,02 мкмоль/л. Роды завершились рождением здорового ребенка.Studies showed that after exacerbation of a herpes virus infection in a pregnant woman, the titer of antibodies to the herpes virus 1: 6400 was determined in the peripheral blood, and the serotonin content was 1.72 ± 0.09 μmol / L; after treatment with immunoglobulin at 16 and 24 weeks, the antibody titer to the herpes virus at 36 weeks of gestation decreased to 1: 1600, and the amount of serotonin in the peripheral blood was 0.56 ± 0.02 μmol / L. Childbirth ended with the birth of a healthy baby.
Таким образом, применяя своевременно для лечения беременной человеческий иммуноглобулин при обострении герпес-вирусной инфекции во II триместре, можно погасить не только агрессивность герпес-вирусной инфекции, но и предотвратить появления в организме беременности большого количества серотонина, повреждающего органы фетоплацентарной системы.Thus, applying human immunoglobulin in a timely manner to treat a pregnant woman with an exacerbation of herpes virus infection in the second trimester, it is possible to suppress not only the aggressiveness of herpes virus infection, but also prevent the appearance of a large amount of serotonin in the body of the pregnancy, which damages the organs of the fetoplacental system.
ЛитератураLiterature
1. Луценко М.Т., Андриевская И.А. Характер обмена серотонина в плаценте при обострении герпес-вирусной инфекции во время беременности // Бюллетень экспер. биологии и медицины. М. №8. 2012. С.221-225.1. Lutsenko M.T., Andrievskaya I.A. The nature of the exchange of serotonin in the placenta during exacerbation of herpes virus infection during pregnancy // Expert Bulletin. biology and medicine. M. No. 8. 2012. S.221-225.
2. Мамедова Н.И. Некоторые аспекты функционирования центральной серотонинэргической системы и действия антидепрессантов - селективных ингибиторов реайпекасеротонина // Мед. консультация. №1. 2001. С.26-29.2. Mamedova N.I. Some aspects of the functioning of the central serotonergic system and the action of antidepressants - selective inhibitors of reipecaserotonin // Med. consultation. No. 1. 2001. S. 26-29.
3. Планельс X., Попенкова З.А. Серотонин и его значение в инфекционной патологии // М. 1965. 201 с.3. Planels X., Popenkova Z.A. Serotonin and its significance in infectious diseases // M. 1965. 201 p.
4. Прошина Л.Я. Исследование гистамина и серотонина в одной пробе крови // Лабораторное дело. №2. 1981. С.90-93.4. Proshina L.Ya. The study of histamine and serotonin in one blood sample // Laboratory. No. 2. 1981. S. 90-93.
5. Соловьева А.С., Луценко М.Т., Андриевская И.А. Фетоплацентарная система при герпес-вирусной инфекции // Дальневосточный мед. журнал. Хабаровск. №1. 2004. С 77-78.5. Solovyova A.S., Lutsenko M.T., Andrievskaya I.A. Fetoplacental system for herpes virus infection // Far Eastern honey. Journal. Khabarovsk No. 1. 2004. From 77-78.
6. Соловьева А.С. Показатели клеточного и гуморального иммунитета у беременных, перенесших герпес-вирусную инфекцию // Бюлл. физиол. и патол. дыхания. Вып.20. 2005. С 7-11.6. Soloviev A.S. Indicators of cellular and humoral immunity in pregnant women undergoing herpes virus infection // Bull. fiziol. and patol. breathing. Issue 20. 2005. From 7-11.
7. Соловьева А.С. Закономерности и механизмы изменений иммунной системы беременных с герпес-вирусной инфекцией // Автореф. дисс. докторской. 2006. 37 с.7. Soloviev A.S. Regularities and mechanisms of changes in the immune system of pregnant women with herpes virus infection // Abstract. diss. doctoral. 2006.37 p.
8. Haigler H.J. Serotonin receptors in the brain. Federal Proceedings. 1977. vol.36. P.21-59.8. Haigler H.J. Serotonin receptors in the brain. Federal Proceedings. 1977. vol. 36. P.21-59.
9. Jenista J.A. Perinatal herpesvirus infection // Semen Perenatology. 1983. vol.7, №1. P.9-15.9. Jenista J.A. Perinatal herpesvirus infection // Semen Perenatology. 1983. vol. 7, No. 1. P.9-15.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012149873/15A RU2530617C2 (en) | 2012-11-22 | 2012-11-22 | Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012149873/15A RU2530617C2 (en) | 2012-11-22 | 2012-11-22 | Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012149873A RU2012149873A (en) | 2014-05-27 |
| RU2530617C2 true RU2530617C2 (en) | 2014-10-10 |
Family
ID=50775188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149873/15A RU2530617C2 (en) | 2012-11-22 | 2012-11-22 | Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2530617C2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2306564C1 (en) * | 2006-05-10 | 2007-09-20 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Method for predicting chronic fetoplacental insufficiency |
| US20080096795A1 (en) * | 1997-05-13 | 2008-04-24 | The Regents Of The University Of California | Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use |
-
2012
- 2012-11-22 RU RU2012149873/15A patent/RU2530617C2/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080096795A1 (en) * | 1997-05-13 | 2008-04-24 | The Regents Of The University Of California | Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use |
| RU2306564C1 (en) * | 2006-05-10 | 2007-09-20 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Method for predicting chronic fetoplacental insufficiency |
Non-Patent Citations (1)
| Title |
|---|
| ЛУЦЕНКО М.Т. и др. "Морфофункциональная характеристика фетоплацентарного комплекса у беременных, перенесших обострение герпес-вирусной инфекции, и патоморфологические изменения в органах плода"// Архив патологии, 2010, том 72, N4, с.47-49. КAMILOVA N et al. Diagnostic indices of fetoplacental complex in pregnancy assessment of women with genital infections// Georgian Med News. 2008 Nov;(164):23-7. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012149873A (en) | 2014-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cárdenes et al. | Senescence of bone marrow-derived mesenchymal stem cells from patients with idiopathic pulmonary fibrosis | |
| Dumbrava et al. | Mesenchymal stromal cell-derived small extracellular vesicles promote neurological recovery and brain remodeling after distal middle cerebral artery occlusion in aged rats | |
| Meng et al. | Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion | |
| Huang et al. | Intrauterine infusion of clinically graded human umbilical cord-derived mesenchymal stem cells for the treatment of poor healing after uterine injury: a phase I clinical trial | |
| Rogovskii | Immune tolerance as the physiologic counterpart of chronic inflammation | |
| Leaw et al. | Human amnion epithelial cells rescue cell death via immunomodulation of microglia in a mouse model of perinatal brain injury | |
| Yang et al. | Hypoxia-inducible factor-1α protects against intervertebral disc degeneration through antagonizing mitochondrial oxidative stress | |
| Sun et al. | Nerve growth factor in combination with Oxiracetam in the treatment of Hypertensive Cerebral Hemorrhage | |
| Cheng et al. | Extracorporeal shock wave therapy combined with platelet-rich plasma during preventive and therapeutic stages of intrauterine adhesion in a rat model | |
| Michaeli et al. | Rejuvenating effect of pregnancy on the mother | |
| Wang et al. | Phenotype shifting in astrocytes account for benefits of intra-arterial selective cooling infusion in hypertensive rats of ischemic stroke | |
| Van Steenwinckel et al. | Key roles of glial cells in the encephalopathy of prematurity | |
| Huang et al. | Dichloroacetate Prevents Sepsis Associated Encephalopathy by Inhibiting Microglia Pyroptosis through PDK4/NLRP3: Huang, Zheng, Wang, Zhao, Liu, Lin, Zhu, Xie, Lv, Wang, and Mo | |
| Lee et al. | Cervical meningomyelitis after lumbar epidural steroid injection | |
| RU2530617C2 (en) | Method for assessing decay of serotonin content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy | |
| Zammarchi et al. | Valacyclovir for prevention and treatment of fetal CMV infection: inclusion in the Law 648/96 list and launch of the Italian multicentre observational prospective study “MEGAL-ITALI” | |
| US20190117698A1 (en) | Methods and compositions for treating vascular-related degenerative neurological disorders | |
| Ejiji et al. | Delayed diagnosis of tuberculous meningitis in a pregnant Nigerian: A case report | |
| RU2517067C1 (en) | Method for assessing decay of fatty acid peroxide content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy | |
| Tuganbekova et al. | Fetal renal stem cell transplant in nephrotic and nonnephrotic glomerulonephritis with stage 2-4 chronic kidney disease: potential effect on proteinuria and glomerular filtration rate | |
| RU2309744C1 (en) | Method for treatment of post-delivery endometritis | |
| Huang et al. | The Conditioned Medium of Umbilical Cord Mesenchymal Stem Cells Diminished the Trau-matic Effects of HUVECs Injured by Indoxyl Sulfate | |
| RU2413523C2 (en) | Method of treating posttraumatic encephalopathy | |
| Ol’ga et al. | Features of hemodynamics of pelvic organs in women with tubal-peritoneal infertility | |
| Johanns | Intrinsic and extrinsic factors affecting cortical development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20140519 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141123 |